Breaking News Instant updates and real-time market news.

F

Ford

$10.18 /

+0.07 (+0.69%)

, VWAGY

Volkswagen

$0.00 /

+ (+0.00%)

09:21
07/12/19
07/12
09:21
07/12/19
09:21

Ford says there is no change to $11B forecast in electric vehicles by 2022

Ford (F) says Europe is moving faster in the mandate for zero emissions. Says was already working for a bespoke platform for Mustang and F-150. Says open to expanded capabilities in Volkswagen (VWAGY) partnership. Says there is no change to $11B forecast in electric vehicles by 2022. Says happy with opportunity to cooperate and also compete with Volkswagen. Comments taken from presentation on Ford and Volkswagen's global collaboration.

F

Ford

$10.18 /

+0.07 (+0.69%)

VWAGY

Volkswagen

$0.00 /

+ (+0.00%)

  • 12

    Jul

  • 12

    Jul

  • 12

    Jul

  • 12

    Jul

  • 24

    Jul

F Ford
$10.18 /

+0.07 (+0.69%)

07/03/19 Morgan Stanley
Ford to begin pivot to battery electric vehicles this year, says Morgan Stanley
06/27/19
Fly Intel: Top five analyst initiations
06/27/19
Credit Suisse bullish on Ford, initiates with an Outperform
06/26/19 Credit Suisse
Ford initiated with an Outperform at Credit Suisse
VWAGY Volkswagen
$0.00 /

+ (+0.00%)

06/27/19 Credit Suisse
Credit Suisse starts Tesla at Underperform, sees 'niche automaker'
06/03/19 RBC Capital
Volkswagen initiated with an Outperform at RBC Capital
05/31/19 JMP Securities
JMP Securities keeps Outperform rating on Tesla after driving Audi e-tron

TODAY'S FREE FLY STORIES

General news
FX Action: USD-CAD has traded firmer » 04:25
08/03/20
08/03
04:25
08/03/20
04:25

FX Action: USD-CAD has…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

General news
FX Update: The dollar has lifted » 03:35
08/03/20
08/03
03:35
08/03/20
03:35

FX Update: The dollar has…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

General news
Japan manufacturing PMI confirmed at 45.2 » 03:05
08/03/20
08/03
03:05
08/03/20
03:05

Japan manufacturing PMI…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

General news
Asian Market Update: » 03:05
08/03/20
08/03
03:05
08/03/20
03:05

Asian Market Update:…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

General news
China Caixin manufacturing PMI higher than expected » 03:05
08/03/20
08/03
03:05
08/03/20
03:05

China Caixin…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

Downgrade
Copel downgraded to Neutral from Buy at Goldman Sachs » 21:20
08/02/20
08/02
21:20
08/02/20
21:20
ELP

Copel

$12.55 /

-0.36 (-2.79%)

, CIG

Cemig

$2.33 /

-0.1 (-4.12%)

Goldman Sachs analyst…

Goldman Sachs analyst Pedro Manfredini downgraded Copel (ELP) to Neutral from Buy with a R$66 price target. The analyst cites valuation for the downgrade. Manfredini now sees Copel as more expensive than comparable peers such as Cemig (CIG), a stock that remains Buy-rated.

ShowHide Related Items >><<
ELP Copel
$12.55 /

-0.36 (-2.79%)

ELP Copel
$12.55 /

-0.36 (-2.79%)

11/14/19 Goldman Sachs
Copel initiated with a Buy at Goldman Sachs
08/26/19
Fly Intel: Top five analyst upgrades
08/26/19 JPMorgan
Copel upgraded to Overweight from Neutral at JPMorgan
CIG Cemig
$2.33 /

-0.1 (-4.12%)

11/14/19 Goldman Sachs
Cemig initiated with a Buy at Goldman Sachs
Upgrade
South State upgraded to Outperform from Market Perform at Keefe Bruyette » 21:14
08/02/20
08/02
21:14
08/02/20
21:14
SSB

South State

$47.66 /

-0.04 (-0.08%)

Keefe Bruyette analyst…

Keefe Bruyette analyst Catherine Mealor upgraded South State to Outperform from Market Perform with a price target of $65, down from $70. The company's "strong" Q1 results with a better outlook for pre-provision net revenue earnings and increase in the allowance for credit losses to 1.96% provide for "significant credit cushion," better than expected tangible book value at deal close and a decrease in deferrals, Mealor tells investors in a research note. As such, the analyst sees South State as better positioned and 40% upside in the shares.

ShowHide Related Items >><<
SSB South State
$47.66 /

-0.04 (-0.08%)

07/01/20 Raymond James
South State initiated with an Outperform at Raymond James
07/01/20 Raymond James
South State initiated with an Outperform at Raymond James
04/24/20 DA Davidson
South State upgraded to Buy from Neutral at DA Davidson
03/06/20 SunTrust
SunTrust cuts price targets on Banks amid lower interest rate environment
SSB South State
$47.66 /

-0.04 (-0.08%)

Downgrade
Varian downgraded to Neutral from Overweight at Piper Sandler » 21:09
08/02/20
08/02
21:09
08/02/20
21:09
VAR

Varian

$142.44 /

+3.9 (+2.82%)

, SMMNY

Siemens Healthineers

$0.00 /

+ (+0.00%)

Piper Sandler analyst…

Piper Sandler analyst Jason Bednar downgraded Varian (VAR) to Neutral from Overweight with a price target of $177.50, up from $142, following the company's agreement to be acquired by Siemens Healthineers (SMMNY). With unanimous Board approval in hand, a "fairly full" deal valuation, and "very few other players" that could pursue such a deal, a competing bid for Varian is unlikely, Bednar tells investors in a research note.

ShowHide Related Items >><<
VAR Varian
$142.44 /

+3.9 (+2.82%)

VAR Varian
$142.44 /

+3.9 (+2.82%)

07/27/20 Piper Sandler
Varian Medical price target raised to $142 from $130 at Piper Sandler
06/18/20 UBS
Varian Medical competitive position remains strong, says UBS
05/12/20 Piper Sandler
Piper Sandler notes goodwill impairment charge for Varian Medical investors
05/05/20 Barrington
Varian Medical price target lowered to $137 from $147 at Barrington
SMMNY Siemens Healthineers
$0.00 /

+ (+0.00%)

07/24/20 UBS
Siemens Healthineers initiated with a Neutral at UBS
07/22/20 RBC Capital
Siemens Healthineers price target raised to EUR 45 from EUR 40 at RBC Capital
07/02/20 JPMorgan
Siemens Healthineers price target lowered to EUR 37.60 at JPMorgan
06/08/20 Citi
Siemens Healthineers upgraded to Buy from Neutral at Citi
VAR Varian
$142.44 /

+3.9 (+2.82%)

Syndicate
VistaGen Therapeutics 15.6M share Secondary priced at 80c » 20:05
08/02/20
08/02
20:05
08/02/20
20:05
VTGN

VistaGen Therapeutics

$0.93 /

+0.0675 (+7.80%)

Maxim Group LLC is acting…

Maxim Group LLC is acting as sole book-running manager for the offering.

ShowHide Related Items >><<
VTGN VistaGen Therapeutics
$0.93 /

+0.0675 (+7.80%)

VTGN VistaGen Therapeutics
$0.93 /

+0.0675 (+7.80%)

11/14/19 William Blair
William Blair downgrades VistaGen to Market Perform after MDD trial miss
11/14/19 William Blair
VistaGen Therapeutics downgraded to Market Perform from Outperform at William Blair
08/28/19 William Blair
VistaGen soars 25% after William Blair initiates with $7 fair value estimate
08/28/19 William Blair
VistaGen Therapeutics initiated with an Outperform at William Blair
Hot Stocks
Fly Intel: Top five weekend stock stories » 19:50
08/02/20
08/02
19:50
08/02/20
19:50
MSFT

Microsoft

$205.00 /

+1.135 (+0.56%)

, MPC

Marathon Petroleum

$38.24 /

+0.165 (+0.43%)

, GOOG

Alphabet

$1,482.46 /

-52.125 (-3.40%)

, GOOGL

Alphabet Class A

$1,487.69 /

-48.81 (-3.18%)

, AMZN

Amazon.com

$3,165.00 /

+114.03 (+3.74%)

, AAPL

Apple

$425.02 /

+39.88 (+10.35%)

, FB

Facebook

$253.82 /

+19.19 (+8.18%)

, AN

AutoNation

$51.31 /

-0.29 (-0.56%)

, GPI

Group 1 Automotive

$83.86 /

-5.985 (-6.66%)

, KMX

CarMax

$96.94 /

-1.34 (-1.36%)

Catch up on the…

Catch up on the weekend's top five stories with this list compiled by The Fly: 1. Microsoft (MSFT) has confirmed that it has held talks with ByteDance to acquire TikTok in the U.S. In a statement, Microsoft said that, "Following a conversation between Microsoft CEO Satya Nadella and President Donald J. Trump, Microsoft is prepared to continue discussions to explore a purchase of TikTok in the United States. Microsoft fully appreciates the importance of addressing the President's concerns. It is committed to acquiring TikTok subject to a complete security review and providing proper economic benefits to the United States, including the United States Treasury. Microsoft will move quickly to pursue discussions with TikTok's parent company, ByteDance, in a matter of weeks, and in any event completing these discussions no later than September 15, 2020. [...] The operating model for the service would be built to ensure transparency to users as well as appropriate security oversight by governments in these countries. Among other measures, Microsoft would ensure that all private data of TikTok's American users is transferred to and remains in the United States. To the extent that any such data is currently stored or backed-up outside the United States, Microsoft would ensure that this data is deleted from servers outside the country after it is transferred." 2. Marathon Petroleum (MPC) announced that it and certain of its subsidiaries have entered into a definitive agreement with 7-Eleven, a wholly owned, indirect subsidiary of Seven & i Holdings, whereby 7-Eleven will acquire Speedway for $21B in cash. The transaction is expected to close in the first quarter of 2021, subject to customary closing conditions and regulatory approvals. 3. On Wednesday, Alphabet's (GOOG; GOOGL) Sundar Pichai, Amazon's (AMZN), Apple's (AAPL) Tim Cook, and Facebook's (FB) Mark Zuckerberg were hauled in front of a virtual Congressional hearing, where they were subjected to more than five hours of cantankerous questions from both sides of the aisle, Eric Savitz wrote in this week's edition of Barron's. But investors basically ignored the proceedings, with all four stocks rising as the hearings went on, the author noted. Less than 24 hours later, investors' confidence was validated, when the same four companies reported their June quarter earnings, posting "impressive, Street-beating sales and profits," he added. Ultimately, there are still regulatory risks for all of these stocks, but the risks seem increasingly modest compared with the enduring appeal of big tech's businesses, the publication contended. 4. Apple is pushing for huge rent reductions across its UK stores despite its sales soaring to new heights during the lockdown, The Sunday Times' Sam Chambers reported. The tech giant has told landlords of a portion of its 38-store estate in the U.K. that it wants rents slashed by up to 50% and a rent-free period. In return, it has offered to extend leases by a few years, the author noted. 5. AutoNation (AN), Group 1 Automotive (GPI) and CarMax (KMX) saw positive mentions in this week's edition of Barron's.

ShowHide Related Items >><<
MSFT Microsoft
$205.00 /

+1.135 (+0.56%)

MPC Marathon Petroleum
$38.24 /

+0.165 (+0.43%)

KMX CarMax
$96.94 /

-1.34 (-1.36%)

GPI Group 1 Automotive
$83.86 /

-5.985 (-6.66%)

GOOGL Alphabet Class A
$1,487.69 /

-48.81 (-3.18%)

GOOG Alphabet
$1,482.46 /

-52.125 (-3.40%)

FB Facebook
$253.82 /

+19.19 (+8.18%)

AN AutoNation
$51.31 /

-0.29 (-0.56%)

AMZN Amazon.com
$3,165.00 /

+114.03 (+3.74%)

AAPL Apple
$425.02 /

+39.88 (+10.35%)

MSFT Microsoft
$205.00 /

+1.135 (+0.56%)

07/31/20 Stifel
Citrix disclosure points to $1B commitment, most likely to Azure, says Stifel
07/27/20 Morgan Stanley
Morgan Stanley downgrades Software industry view to In-Line from Attractive
07/23/20
Fly Intel: Top five analyst downgrades
07/23/20 Wedbush
Microsoft remains top cloud name at Wedbush
MPC Marathon Petroleum
$38.24 /

+0.165 (+0.43%)

07/15/20 Morgan Stanley
MPLX downgraded to Equal Weight from Overweight at Morgan Stanley
05/13/20 Morgan Stanley
U.S. gasoline consumption appears to have bottomed, says Morgan Stanley
04/24/20 Citi
Marathon Petroleum downgraded to Neutral from Buy at Citi
03/24/20 Raymond James
Marathon Petroleum double downgraded to Market Perform at Raymond James
GOOG Alphabet
$1,482.46 /

-52.125 (-3.40%)

07/31/20
Fly Intel: Top five analyst downgrades
07/31/20 Guggenheim
Alphabet price target raised to $1,725 from $1,580 at Guggenheim
07/31/20 Raymond James
Alphabet price target raised to $1,700 from $1,425 at Raymond James
07/31/20 Oppenheimer
Alphabet price target raised to $1,685 from $1,445 at Oppenheimer
GOOGL Alphabet Class A
$1,487.69 /

-48.81 (-3.18%)

07/31/20 RBC Capital
Alphabet price target raised to $1,700 from $1,500 at RBC Capital
07/31/20 Morgan Stanley
Alphabet price target raised to $1,760 from $1,700 at Morgan Stanley
07/31/20 Barclays
Alphabet price target raised to $1,800 from $1,600 at Barclays
AMZN Amazon.com
$3,165.00 /

+114.03 (+3.74%)

07/31/20 BMO Capital
Amazon.com price target raised to $3,700 from $3,500 at BMO Capital
07/31/20 RBC Capital
Amazon.com price target raised to $3,800 from $3,300 at RBC Capital
07/31/20 Guggenheim
Amazon.com price target raised to $3,600 from $2,700 at Guggenheim
07/31/20 Goldman Sachs
Amazon.com price target raised to $4,200 from $3,800 at Goldman Sachs
AAPL Apple
$425.02 /

+39.88 (+10.35%)

07/31/20 Canaccord
Canaccord boosts Apple target to $460 after 'impressive' quarter
07/31/20 RBC Capital
Apple price target raised to $445 from $390 at RBC Capital
07/31/20
Apple price target raised to $460 from $425 at JPMorgan
07/31/20 Loop Capital
Apple price target raised to $376 from $330 at Loop Capital
FB Facebook
$253.82 /

+19.19 (+8.18%)

07/31/20
Facebook price target raised to $300 from $290 at JPMorgan
07/31/20 Wedbush
Facebook price target raised to $300 from $250 at Wedbush
07/31/20 RBC Capital
Facebook price target raised to $320 from $271 at RBC Capital
07/31/20 Raymond James
Facebook price target raised to $280 from $240 at Raymond James
AN AutoNation
$51.31 /

-0.29 (-0.56%)

07/24/20
Fly Intel: Top five analyst upgrades
07/24/20 SunTrust
AutoNation price target raised to $55 from $42 at SunTrust
07/24/20 JPMorgan
AutoNation upgraded to Overweight from Neutral at JPMorgan
07/17/20
Fly Intel: Top five analyst downgrades
GPI Group 1 Automotive
$83.86 /

-5.985 (-6.66%)

07/08/20 JPMorgan
Group 1 Automotive price target lowered to $94 from $95 at JPMorgan
06/26/20 Benchmark
Group 1 Automotive price target raised to $100 from $79 at Benchmark
06/26/20 JPMorgan
Group 1 Automotive price target raised to $95 from $83 at JPMorgan
03/11/20 Morgan Stanley
Morgan Stanley cuts estimates for GM, Ford and FCA on coronavirus 'demand shock'
KMX CarMax
$96.94 /

-1.34 (-1.36%)

07/02/20 Oppenheimer
CarMax price target raised to $108 from $87 at Oppenheimer
06/24/20 Jefferies
CarMax, AutoNation could be eyeing Hertz in bankruptcy, says Jefferies
06/23/20 Argus
CarMax price target raised to $105 from $75 at Argus
06/22/20 RBC Capital
CarMax price target raised to $100 from $80 at RBC Capital
MSFT Microsoft
$205.00 /

+1.135 (+0.56%)

MPC Marathon Petroleum
$38.24 /

+0.165 (+0.43%)

KMX CarMax
$96.94 /

-1.34 (-1.36%)

GPI Group 1 Automotive
$83.86 /

-5.985 (-6.66%)

GOOG Alphabet
$1,482.46 /

-52.125 (-3.40%)

FB Facebook
$253.82 /

+19.19 (+8.18%)

AN AutoNation
$51.31 /

-0.29 (-0.56%)

AMZN Amazon.com
$3,165.00 /

+114.03 (+3.74%)

AAPL Apple
$425.02 /

+39.88 (+10.35%)

MSFT Microsoft
$205.00 /

+1.135 (+0.56%)

MPC Marathon Petroleum
$38.24 /

+0.165 (+0.43%)

GOOG Alphabet
$1,482.46 /

-52.125 (-3.40%)

FB Facebook
$253.82 /

+19.19 (+8.18%)

AN AutoNation
$51.31 /

-0.29 (-0.56%)

AMZN Amazon.com
$3,165.00 /

+114.03 (+3.74%)

AAPL Apple
$425.02 /

+39.88 (+10.35%)

MSFT Microsoft
$205.00 /

+1.135 (+0.56%)

MPC Marathon Petroleum
$38.24 /

+0.165 (+0.43%)

KMX CarMax
$96.94 /

-1.34 (-1.36%)

GOOGL Alphabet Class A
$1,487.69 /

-48.81 (-3.18%)

GOOG Alphabet
$1,482.46 /

-52.125 (-3.40%)

AN AutoNation
$51.31 /

-0.29 (-0.56%)

AAPL Apple
$425.02 /

+39.88 (+10.35%)

MSFT Microsoft
$205.00 /

+1.135 (+0.56%)

MPC Marathon Petroleum
$38.24 /

+0.165 (+0.43%)

KMX CarMax
$96.94 /

-1.34 (-1.36%)

GOOGL Alphabet Class A
$1,487.69 /

-48.81 (-3.18%)

GOOG Alphabet
$1,482.46 /

-52.125 (-3.40%)

FB Facebook
$253.82 /

+19.19 (+8.18%)

AN AutoNation
$51.31 /

-0.29 (-0.56%)

AMZN Amazon.com
$3,165.00 /

+114.03 (+3.74%)

AAPL Apple
$425.02 /

+39.88 (+10.35%)

MSFT Microsoft
$205.00 /

+1.135 (+0.56%)

GOOG Alphabet
$1,482.46 /

-52.125 (-3.40%)

AMZN Amazon.com
$3,165.00 /

+114.03 (+3.74%)

Hot Stocks
Marathon Petroleum announces agreement for $21B sale of Speedway » 19:42
08/02/20
08/02
19:42
08/02/20
19:42
MPC

Marathon Petroleum

$38.24 /

+0.165 (+0.43%)

Marathon Petroleum…

Marathon Petroleum announced that it and certain of its subsidiaries have entered into a definitive agreement with 7-Eleven, a wholly owned, indirect subsidiary of Seven & i Holdings, whereby 7-Eleven will acquire Speedway for $21B in cash. The transaction is expected to close in the first quarter of 2021, subject to customary closing conditions and regulatory approvals.

ShowHide Related Items >><<
MPC Marathon Petroleum
$38.24 /

+0.165 (+0.43%)

MPC Marathon Petroleum
$38.24 /

+0.165 (+0.43%)

07/15/20 Morgan Stanley
MPLX downgraded to Equal Weight from Overweight at Morgan Stanley
05/13/20 Morgan Stanley
U.S. gasoline consumption appears to have bottomed, says Morgan Stanley
04/24/20 Citi
Marathon Petroleum downgraded to Neutral from Buy at Citi
03/24/20 Raymond James
Marathon Petroleum double downgraded to Market Perform at Raymond James
MPC Marathon Petroleum
$38.24 /

+0.165 (+0.43%)

MPC Marathon Petroleum
$38.24 /

+0.165 (+0.43%)

MPC Marathon Petroleum
$38.24 /

+0.165 (+0.43%)

MPC Marathon Petroleum
$38.24 /

+0.165 (+0.43%)

Periodicals
Marathon Petroleum to sell gas-station chain to 7-Eleven owners, WSJ reports » 19:38
08/02/20
08/02
19:38
08/02/20
19:38
MPC

Marathon Petroleum

$38.24 /

+0.165 (+0.43%)

Marathon Petroleum said…

Marathon Petroleum said it has agreed to sell its gas stations to the owners of the 7-Eleven convenience store chain for $21B in the largest U.S. energy-related deal of the year, The Wall Street Journal's Rebecca Elliot reports. The all-cash agreement with 7-Eleven comes less than a year after Marathon agreed to spin off its convenience-store chain, known as Speedway, under pressure from activist investors including Elliott Management, the author notes.Reference Link

ShowHide Related Items >><<
MPC Marathon Petroleum
$38.24 /

+0.165 (+0.43%)

MPC Marathon Petroleum
$38.24 /

+0.165 (+0.43%)

07/15/20 Morgan Stanley
MPLX downgraded to Equal Weight from Overweight at Morgan Stanley
05/13/20 Morgan Stanley
U.S. gasoline consumption appears to have bottomed, says Morgan Stanley
04/24/20 Citi
Marathon Petroleum downgraded to Neutral from Buy at Citi
03/24/20 Raymond James
Marathon Petroleum double downgraded to Market Perform at Raymond James
MPC Marathon Petroleum
$38.24 /

+0.165 (+0.43%)

MPC Marathon Petroleum
$38.24 /

+0.165 (+0.43%)

MPC Marathon Petroleum
$38.24 /

+0.165 (+0.43%)

MPC Marathon Petroleum
$38.24 /

+0.165 (+0.43%)

Hot Stocks
Microsoft confirms talks to acquire TikTok in U.S., possible deal by Sept. 15 » 19:35
08/02/20
08/02
19:35
08/02/20
19:35
MSFT

Microsoft

$205.00 /

+1.135 (+0.56%)

Microsoft has confirmed…

Microsoft has confirmed that it has held talks with ByteDance to acquire TIkTok in the U.S. In a statement, Microsoft said that, "Following a conversation between Microsoft CEO Satya Nadella and President Donald J. Trump, Microsoft is prepared to continue discussions to explore a purchase of TikTok in the United States. Microsoft fully appreciates the importance of addressing the President's concerns. It is committed to acquiring TikTok subject to a complete security review and providing proper economic benefits to the United States, including the United States Treasury. Microsoft will move quickly to pursue discussions with TikTok's parent company, ByteDance, in a matter of weeks, and in any event completing these discussions no later than September 15, 2020. During this process, Microsoft looks forward to continuing dialogue with the United States Government, including with the President. The discussions with ByteDance will build upon a notification made by Microsoft and ByteDance to the Committee on Foreign Investment in the United States (CFIUS). The two companies have provided notice of their intent to explore a preliminary proposal that would involve a purchase of the TikTok service in the United States, Canada, Australia, and New Zealand and would result in Microsoft owning and operating TikTok in these markets. Microsoft may invite other American investors to participate on a minority basis in this purchase. This new structure would build on the experience TikTok users currently love, while adding world-class security, privacy, and digital safety protections. The operating model for the service would be built to ensure transparency to users as well as appropriate security oversight by governments in these countries. Among other measures, Microsoft would ensure that all private data of TikTok's American users is transferred to and remains in the United States. To the extent that any such data is currently stored or backed-up outside the United States, Microsoft would ensure that this data is deleted from servers outside the country after it is transferred. " Reference Link

ShowHide Related Items >><<
MSFT Microsoft
$205.00 /

+1.135 (+0.56%)

MSFT Microsoft
$205.00 /

+1.135 (+0.56%)

07/31/20 Stifel
Citrix disclosure points to $1B commitment, most likely to Azure, says Stifel
07/27/20 Morgan Stanley
Morgan Stanley downgrades Software industry view to In-Line from Attractive
07/23/20
Fly Intel: Top five analyst downgrades
07/23/20 Wedbush
Microsoft remains top cloud name at Wedbush
MSFT Microsoft
$205.00 /

+1.135 (+0.56%)

MSFT Microsoft
$205.00 /

+1.135 (+0.56%)

MSFT Microsoft
$205.00 /

+1.135 (+0.56%)

MSFT Microsoft
$205.00 /

+1.135 (+0.56%)

MSFT Microsoft
$205.00 /

+1.135 (+0.56%)

Earnings
Legend Biotech expects to record loss of ($89M)-($103M) in first half of 2020 » 16:39
08/02/20
08/02
16:39
08/02/20
16:39
LEGN

Legend Biotech

$35.15 /

-0.805 (-2.24%)

Legend Biotech has…

Legend Biotech has announced preliminary results for the first half of 2020. For the six months ended June 30, 2020, Legend Biotech expects to record a loss from approximately ($89M)-($103M) from continuous operations, including research and development expenses of approximately $96.5M-$111.8M. In addition, Legend Biotech expects to report a one-time non-cash charge of approximately $80M caused by the changes of fair value of Series A Preferred Shares, which was derived from the automatic conversion of all outstanding Series A Preferred Shares into ordinary shares, par value $0.0001 per share, of Legend Biotech upon Legend Biotech's listing on the Nasdaq Global Market. As of June 30, 2020, Legend Biotech had approximately $562.4M of cash and cash equivalents and approximately $75.6M in time deposits.

ShowHide Related Items >><<
LEGN Legend Biotech
$35.15 /

-0.805 (-2.24%)

LEGN Legend Biotech
$35.15 /

-0.805 (-2.24%)

07/01/20 JPMorgan
Legend Biotech initiated with an Overweight at JPMorgan
07/01/20 Jefferies
Legend Biotech initiated with a Buy at Jefferies
06/30/20 Morgan Stanley
Legend Biotech initiated with an Overweight at Morgan Stanley
LEGN Legend Biotech
$35.15 /

-0.805 (-2.24%)

  • 05
    Jun
LEGN Legend Biotech
$35.15 /

-0.805 (-2.24%)

Periodicals
Deutsche opens review into personal banker to Trump, Kushner, NY Times reports » 16:35
08/02/20
08/02
16:35
08/02/20
16:35
DB

Deutsche Bank

$8.93 /

-0.075 (-0.83%)

Deutsche Bank has opened…

Deutsche Bank has opened an internal investigation into the longtime personal banker of President Trump and his son-in-law, Jared Kushner, over a 2013 real estate transaction between the banker and a company part-owned by Kushner, The New York Times' Jesse Drucker and David Enrich report. Reference Link

ShowHide Related Items >><<
DB Deutsche Bank
$8.93 /

-0.075 (-0.83%)

DB Deutsche Bank
$8.93 /

-0.075 (-0.83%)

07/30/20 Morgan Stanley
Deutsche Bank price target raised to EUR 7.50 from EUR 7 at Morgan Stanley
07/21/20 Barclays
Deutsche Bank price target raised to EUR 4.50 from EUR 4 at Barclays
07/08/20 Morgan Stanley
Deutsche Bank price target raised to EUR 7 from EUR 6 at Morgan Stanley
07/02/20
Fly Intel: Top five analyst downgrades
DB Deutsche Bank
$8.93 /

-0.075 (-0.83%)

DB Deutsche Bank
$8.93 /

-0.075 (-0.83%)

DB Deutsche Bank
$8.93 /

-0.075 (-0.83%)

Periodicals
Samsung, Apple to boost cellphone manufacturing in India, Bloomberg reports » 16:10
08/02/20
08/02
16:10
08/02/20
16:10
SSNLF

Samsung

$0.00 /

+ (+0.00%)

, AAPL

Apple

$425.02 /

+39.88 (+10.35%)

Samsung (SSNLF) and…

Samsung (SSNLF) and Apple's (AAPL) assembly partners are among 22 companies that have pledged $1.5B of investments to set up mobile phone manufacturing units in India, Bloomberg's Kartik Goyal and Santosh Kumar report. Foxconn Technology, Wistron Corp. and Pegatron Corp., all iPhone assemblers, are among companies picked to make smartphones under a production-linked incentive plan, Ravi Shankar Prasad, minister for electronics and information technology, said at a press conference in New Delhi Saturday. The incentives are aimed at encouraging global companies to shift their manufacturing beyond China after a pandemic-induced trade war put the focus on the risks to supply chains, the authors note. Reference Link

ShowHide Related Items >><<
SSNLF Samsung
$0.00 /

+ (+0.00%)

AAPL Apple
$425.02 /

+39.88 (+10.35%)

SSNLF Samsung
$0.00 /

+ (+0.00%)

07/14/20 SunTrust
Maxim Integrated price target raised to $73 from $55 at SunTrust
07/08/20 JPMorgan
Nokia downgraded to Neutral from Overweight at JPMorgan
07/06/20 Rosenblatt
Samsung on track to replace Nokia as 5G RAN supplier at Verizon, says Rosenblatt
06/19/20 Benchmark
Benchmark says Samsung's NAND chip issues likely positive for HDD makers
AAPL Apple
$425.02 /

+39.88 (+10.35%)

07/31/20 Canaccord
Canaccord boosts Apple target to $460 after 'impressive' quarter
07/31/20 RBC Capital
Apple price target raised to $445 from $390 at RBC Capital
07/31/20
Apple price target raised to $460 from $425 at JPMorgan
07/31/20 Loop Capital
Apple price target raised to $376 from $330 at Loop Capital
SSNLF Samsung
$0.00 /

+ (+0.00%)

AAPL Apple
$425.02 /

+39.88 (+10.35%)

SSNLF Samsung
$0.00 /

+ (+0.00%)

AAPL Apple
$425.02 /

+39.88 (+10.35%)

SSNLF Samsung
$0.00 /

+ (+0.00%)

AAPL Apple
$425.02 /

+39.88 (+10.35%)

AAPL Apple
$425.02 /

+39.88 (+10.35%)

AAPL Apple
$425.02 /

+39.88 (+10.35%)

Hot Stocks
Immunic reports top-line data from Phase 2 EMPhASIS trial of IMU-838 in RRMS » 16:02
08/02/20
08/02
16:02
08/02/20
16:02
IMUX

Immunic

$17.20 /

-0.21 (-1.21%)

Immunic announced…

Immunic announced top-line data from its phase 2 EMPhASIS trial of lead asset, IMU-838, the company's selective oral DHODH inhibitor, in patients with relapsing-remitting multiple sclerosis. The study achieved all primary and key secondary endpoints, indicating activity in RRMS patients. In particular, the study met its primary endpoint, demonstrating a statistically significant reduction in the cumulative number of combined unique active magnetic resonance imaging lesions up to week 24 in patients receiving 45mg of IMU-838 once daily, by 62%, as compared to placebo. The study also met its key secondary endpoint, showing a statistically significant reduction in the cumulative number of CUA MRI lesions for the 30mg once daily dose, by 70%, as compared to placebo. All other secondary endpoints, including those based on other MRI parameters and on clinical endpoints such as relapse events, also provided a noticeable signal and numerical benefit for the IMU-838 treatment groups, as compared to placebo. Given the study's design, sample size and the patient's follow-up duration, full statistical analysis of these secondary endpoints was not deemed appropriate or included in the analysis plan. Nonetheless, the company believes "data on these endpoints provides useful information for the further development path toward potential approval." Consistent with prior data sets in other patient populations, administration of IMU-838 in this trial was observed to be safe and well-tolerated. Immunic also said that R&D Expenses were $10M for the three months ended June 30, 2020, as compared to $6M for the same period ended June 30, 2019. For the six months ended June 30, 2020, R&D expenses were $16.4M compared to $9.4M for the same period ended June 30, 2019. Net Loss for the three months ended June 30, 2020 was approximately $11.5M, or 90c per basic and diluted share, based on 12,695,989 weighted average common shares outstanding, compared to a net loss of approximately $14.7M, or $1.52 per basic and diluted share, based on 9,669,129 weighted average common shares outstanding for the same period ended June 30, 2019. Net loss for the six months ended June 30, 2020 was approximately $19.9M, or $1.70 per basic and diluted share, based on 11,722,725 weighted average common shares outstanding, compared to a net loss of approximately $19M, or $3.60 per basic and dilutes share, based on 5,282,412 weighted average common shares outstanding for the same period ended June 30, 2019. Cash and Cash Equivalents, as of June 30, 2020, were $48.6M, which management expects to be sufficient to fund operations beyond twelve months from the date of the issuance of this earnings release.

ShowHide Related Items >><<
IMUX Immunic
$17.20 /

-0.21 (-1.21%)

IMUX Immunic
$17.20 /

-0.21 (-1.21%)

07/20/20
Fly Intel: Top five analyst initiations
07/20/20 BMO Capital
Immunic initiated with an Outperform at BMO Capital
06/04/20 Wedbush
Wedbush starts Immunic at Outperform with $59 price target
06/04/20 Wedbush
Immunic initiated with an Outperform at Wedbush
IMUX Immunic
$17.20 /

-0.21 (-1.21%)

  • 10
    Jun
IMUX Immunic
$17.20 /

-0.21 (-1.21%)

Hot Stocks
Legend Biotech appoints Frank Zhang as new CEO » 15:40
08/02/20
08/02
15:40
08/02/20
15:40
LEGN

Legend Biotech

$35.15 /

-0.805 (-2.24%)

Legend Biotech announced…

Legend Biotech announced that its Board of Directors has appointed Frank Zhang to serve as Chief Executive Officer, effective immediately. Zhang will succeed Yuan Xu, who has resigned from her position as Chief Executive Officer for personal reasons. Xu has also resigned from the Board of Directors of Legend Biotech.

ShowHide Related Items >><<
LEGN Legend Biotech
$35.15 /

-0.805 (-2.24%)

07/01/20 JPMorgan
Legend Biotech initiated with an Overweight at JPMorgan
07/01/20 Jefferies
Legend Biotech initiated with a Buy at Jefferies
06/30/20 Morgan Stanley
Legend Biotech initiated with an Overweight at Morgan Stanley
LEGN Legend Biotech
$35.15 /

-0.805 (-2.24%)

  • 05
    Jun
LEGN Legend Biotech
$35.15 /

-0.805 (-2.24%)

Earnings
Legend Biotech expects to record loss of $89M-$103M in first half of 2020 » 15:38
08/02/20
08/02
15:38
08/02/20
15:38
LEGN

Legend Biotech

$35.15 /

-0.805 (-2.24%)

Legend Biotech has…

Legend Biotech has announced preliminary results for the first half of 2020. For the six months ended June 30, 2020, Legend Biotech expects to record a loss from approximately $89M-$103M from continuous operations, including research and development expenses of approximately $96.5M-$111.8M. In addition, Legend Biotech expects to report a one-time non-cash charge of approximately $80M caused by the changes of fair value of Series A Preferred Shares, which was derived from the automatic conversion of all outstanding Series A Preferred Shares into ordinary shares, par value $0.0001 per share, of Legend Biotech upon Legend Biotech's listing on the Nasdaq Global Market. As of June 30, 2020, Legend Biotech had approximately $562.4M of cash and cash equivalents and approximately $75.6M in time deposits.

ShowHide Related Items >><<
LEGN Legend Biotech
$35.15 /

-0.805 (-2.24%)

07/01/20 JPMorgan
Legend Biotech initiated with an Overweight at JPMorgan
07/01/20 Jefferies
Legend Biotech initiated with a Buy at Jefferies
06/30/20 Morgan Stanley
Legend Biotech initiated with an Overweight at Morgan Stanley
  • 05
    Jun
LEGN Legend Biotech
$35.15 /

-0.805 (-2.24%)

Periodicals
SoftBank to keep stake in Arm after partial sale, Nikkei reports » 14:57
08/02/20
08/02
14:57
08/02/20
14:57
SFTBY

SoftBank

$0.00 /

+ (+0.00%)

, NVDA

Nvidia

$424.58 /

+0.21 (+0.05%)

, TMUS

T-Mobile

$107.38 /

+1.97 (+1.87%)

SoftBank (SFTBY) plans to…

SoftBank (SFTBY) plans to maintain a stake in U.K. chip designer Arm, which has formed the core of its strategic investments in artificial intelligence, even if it sells a partial interest to Nvidia (NVDA) or through an initial public offering, according to Nikkei. SoftBank was already considering an IPO of Arm in the next few years when it was approached by Nvidia last month, sources said. A sale would not be part of SoftBank's current $41B asset monetization program, which it has already made progress by selling shares in T-Mobile (TMUS) and other companies, the publication adds. Reference Link

ShowHide Related Items >><<
TMUS T-Mobile
$107.38 /

+1.97 (+1.87%)

SFTBY SoftBank
$0.00 /

+ (+0.00%)

NVDA Nvidia
$424.58 /

+0.21 (+0.05%)

SFTBY SoftBank
$0.00 /

+ (+0.00%)

07/10/20 Nomura Instinet
SoftBank price target raised to 7,240 yen from 6,640 yen at Nomura Instinet
05/26/20 Citi
SoftBank price target lowered to 7,100 yen from 8,200 yen at Citi
03/24/20 Jefferies
SoftBank upgraded to Buy from Hold at Jefferies
02/13/20 HSBC
SoftBank price target raised to 7,000 yen after Sprint deal approval
NVDA Nvidia
$424.58 /

+0.21 (+0.05%)

07/24/20 Raymond James
Intel 7nm delay positive for AMD, TSMC, Nvidia, says Raymond James
07/24/20 BMO Capital
Intel price target lowered to $50 from $55 at BMO Capital
07/14/20 Cowen
Nvidia price target raised to $475 from $410 at Cowen
07/10/20 RBC Capital
Nvidia price target raised to $461 from $385 at RBC Capital
TMUS T-Mobile
$107.38 /

+1.97 (+1.87%)

07/29/20
Fly Intel: Top five analyst initiations
07/29/20
Fly Intel: Top five analyst downgrades
07/29/20 Deutsche Bank
T-Mobile initiated with a Buy at Deutsche Bank
07/29/20
T-Mobile downgraded to Sector Perform at RBC Capital on 'full valuation'
TMUS T-Mobile
$107.38 /

+1.97 (+1.87%)

NVDA Nvidia
$424.58 /

+0.21 (+0.05%)

  • 24
    Jun
TMUS T-Mobile
$107.38 /

+1.97 (+1.87%)

SFTBY SoftBank
$0.00 /

+ (+0.00%)

TMUS T-Mobile
$107.38 /

+1.97 (+1.87%)

SFTBY SoftBank
$0.00 /

+ (+0.00%)

NVDA Nvidia
$424.58 /

+0.21 (+0.05%)

TMUS T-Mobile
$107.38 /

+1.97 (+1.87%)

NVDA Nvidia
$424.58 /

+0.21 (+0.05%)

Periodicals
Apple asks U.K. store landlords to halve rent, The Sunday Times reports » 14:46
08/02/20
08/02
14:46
08/02/20
14:46
AAPL

Apple

$425.02 /

+39.88 (+10.35%)

Apple is pushing for huge…

Apple is pushing for huge rent reductions across its UK stores despite its sales soaring to new heights during the lockdown, The Sunday Times' Sam Chambers reports. The tech giant has told landlords of a portion of its 38-store estate in the U.K. that it wants rents slashed by up to 50% and a rent-free period. In return, it has offered to extend leases by a few years, the author notes. Reference Link

ShowHide Related Items >><<
AAPL Apple
$425.02 /

+39.88 (+10.35%)

AAPL Apple
$425.02 /

+39.88 (+10.35%)

07/31/20 Canaccord
Canaccord boosts Apple target to $460 after 'impressive' quarter
07/31/20 RBC Capital
Apple price target raised to $445 from $390 at RBC Capital
07/31/20
Apple price target raised to $460 from $425 at JPMorgan
07/31/20 Loop Capital
Apple price target raised to $376 from $330 at Loop Capital
AAPL Apple
$425.02 /

+39.88 (+10.35%)

AAPL Apple
$425.02 /

+39.88 (+10.35%)

AAPL Apple
$425.02 /

+39.88 (+10.35%)

AAPL Apple
$425.02 /

+39.88 (+10.35%)

AAPL Apple
$425.02 /

+39.88 (+10.35%)

Periodicals
Trump may allow Microsoft to buy TikTok's U.S. operations, Barron's says » 14:38
08/02/20
08/02
14:38
08/02/20
14:38
MSFT

Microsoft

$205.00 /

+1.135 (+0.56%)

President Trump, who said…

President Trump, who said Friday night that he'll ban TikTok, may allow Microsoft to buy the app's U.S. operations if there's "complete separation" from the original Beijing-based company, Axios' Mike Allen and Dan Primack report, citing Republican sources. Conversations with Republicans over the weekend suggest a possible blueprint for making the proposed Microsoft deal palatable to the White House, including Microsoft promising a complete break from the Chinese parent company ByteDance and no lingering connection of any kind to ByteDance or non-U.S. TikTok. Reference Link

ShowHide Related Items >><<
MSFT Microsoft
$205.00 /

+1.135 (+0.56%)

MSFT Microsoft
$205.00 /

+1.135 (+0.56%)

07/31/20 Stifel
Citrix disclosure points to $1B commitment, most likely to Azure, says Stifel
07/27/20 Morgan Stanley
Morgan Stanley downgrades Software industry view to In-Line from Attractive
07/23/20
Fly Intel: Top five analyst downgrades
07/23/20 Wedbush
Microsoft remains top cloud name at Wedbush
MSFT Microsoft
$205.00 /

+1.135 (+0.56%)

MSFT Microsoft
$205.00 /

+1.135 (+0.56%)

MSFT Microsoft
$205.00 /

+1.135 (+0.56%)

MSFT Microsoft
$205.00 /

+1.135 (+0.56%)

MSFT Microsoft
$205.00 /

+1.135 (+0.56%)

Hot Stocks
Xencor earns milestone payment from MorphoSys for FDA approval of Monjuvi » 14:22
08/02/20
08/02
14:22
08/02/20
14:22
XNCR

Xencor

$30.02 /

-1.69 (-5.33%)

, MOR

MorphoSys

$32.11 /

-0.715 (-2.18%)

, INCY

Incyte

$98.76 /

-1.63 (-1.62%)

Xencor (XNCR) announced…

Xencor (XNCR) announced that the U.S. Food and Drug Administration approved MorphoSys' (MOR) Monjuvi, a CD19-directed cytolytic antibody indicated in combination with lenalidomide for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma not otherwise specified, including DLBCL arising from low grade lymphoma, and who are not eligible for autologous stem cell transplant. The most common adverse reactions are neutropenia, fatigue, anemia, diarrhea, thrombocytopenia, cough, pyrexia, peripheral edema, respiratory tract infection, and decreased appetite. Xencor has earned a $25M milestone payment from MorphoSys under the license agreement between the companies for Monjuvi in connection with the regulatory approval. Xencor licensed exclusive worldwide rights to develop and commercialize Monjuvi, product code MOR208 and previously XmAb5574, to MorphoSys in 2010. Monjuvi incorporates Xencor's XmAb engineered Fc domain, which mediates B-cell lysis through apoptosis and immune effector mechanism including antibody-dependent cell-mediated cytotoxicity and antibody-dependent cellular phagocytosis. Xencor is eligible to receive royalties on worldwide net sales in the high-single to low-double digit percent range and additional development, regulatory and sales milestone payments. Monjuvi will be co-commercialized in the U.S. by MorphoSys and Incyte (INCY). The European Marketing Authorization Application for tafasitamab, based on data from the L-MIND study and supported by the Re-MIND observational retrospective study, is currently under review by the European Medicines Agency.

ShowHide Related Items >><<
XNCR Xencor
$30.02 /

-1.69 (-5.33%)

MOR MorphoSys
$32.11 /

-0.715 (-2.18%)

INCY Incyte
$98.76 /

-1.63 (-1.62%)

XNCR Xencor
$30.02 /

-1.69 (-5.33%)

07/08/20 Piper Sandler
Xencor, Atreca deal offers synergies for XmAb design, says Piper Sandler
06/22/20 Piper Sandler
Xencor's '2+1' biospecific antibodies ideal for solid tumors, says Piper Sandler
05/13/20 Piper Sandler
Xencor's XmAb20717 shows first-ever clinical benefit, says Piper Sandler
03/04/20 Barclays
Barclays starts small, mid cap Biotechnology sector with Positive view
MOR MorphoSys
$32.11 /

-0.715 (-2.18%)

06/25/20 RBC Capital
MorphoSys downgraded to Sector Perform from Outperform at RBC Capital
05/13/20 Barclays
MorphoSys price target raised to EUR 105 from EUR 100 at Barclays
05/12/20 HSBC
MorphoSys upgraded to Hold from Reduce at HSBC
03/25/20 Oppenheimer
Incyte price target lowered to $85 from $99 at Oppenheimer
INCY Incyte
$98.76 /

-1.63 (-1.62%)

07/23/20 Stifel
Incyte REACH3 'nice incremental surprise,' not narrative-changing, says Stifel
07/23/20 Piper Sandler
Piper says Incyte cements 'all-around win for Jakafi' with REACH3 results
07/20/20 Credit Suisse
Incyte price target raised to $100 from $88 at Credit Suisse
06/16/20
Fly Intel: Top five analyst initiations
XNCR Xencor
$30.02 /

-1.69 (-5.33%)

MOR MorphoSys
$32.11 /

-0.715 (-2.18%)

INCY Incyte
$98.76 /

-1.63 (-1.62%)

MOR MorphoSys
$32.11 /

-0.715 (-2.18%)

XNCR Xencor
$30.02 /

-1.69 (-5.33%)

MOR MorphoSys
$32.11 /

-0.715 (-2.18%)

INCY Incyte
$98.76 /

-1.63 (-1.62%)

INCY Incyte
$98.76 /

-1.63 (-1.62%)

Hot Stocks
MorphoSys announces FDA approval of Monjuvi, Lenalidomide combo » 14:17
08/02/20
08/02
14:17
08/02/20
14:17
INCY

Incyte

$98.76 /

-1.63 (-1.62%)

, MOR

MorphoSys

$32.11 /

-0.715 (-2.18%)

MorphoSys (MOR) announced…

MorphoSys (MOR) announced that the U.S. Food and Drug Administration has approved Monjuvi in combination with lenalidomide for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma not otherwise specified, including DLBCL arising from low grade lymphoma, and who are not eligible for autologous stem cell transplant. Monjuvi, a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, has been approved under accelerated approval by the U.S. FDA based on overall response rate. Continued approval may be contingent upon verification and description of clinical benefit in a confirmatory trial or trials. The FDA decision represents the first approval of a second-line treatment for adult patients who progressed during or after first-line therapy. The FDA approval was based on data from the MorphoSys-sponsored Phase 2 L-MIND study, an open label, multicenter, single arm trial of Monjuvi in combination with lenalidomide as a treatment for adult patients with relapsed or refractory DLBCL. The FDA previously granted Fast Track and Breakthrough Therapy Designation for this combination in relapsed or refractory DLBCL, and the Biologics License Application for Monjuviwas granted Priority Review and approved under the FDA's Accelerated Approval program. Monjuvi is expected to be commercially available in the United States shortly. MorphoSys and its partner Incyte (INCY) will co-commercialize Monjuvi in the United States. Incyte has exclusive commercialization rights outside the United States.

ShowHide Related Items >><<
MOR MorphoSys
$32.11 /

-0.715 (-2.18%)

INCY Incyte
$98.76 /

-1.63 (-1.62%)

INCY Incyte
$98.76 /

-1.63 (-1.62%)

07/23/20 Stifel
Incyte REACH3 'nice incremental surprise,' not narrative-changing, says Stifel
07/23/20 Piper Sandler
Piper says Incyte cements 'all-around win for Jakafi' with REACH3 results
07/20/20 Credit Suisse
Incyte price target raised to $100 from $88 at Credit Suisse
06/16/20
Fly Intel: Top five analyst initiations
MOR MorphoSys
$32.11 /

-0.715 (-2.18%)

06/25/20 RBC Capital
MorphoSys downgraded to Sector Perform from Outperform at RBC Capital
05/13/20 Barclays
MorphoSys price target raised to EUR 105 from EUR 100 at Barclays
05/12/20 HSBC
MorphoSys upgraded to Hold from Reduce at HSBC
03/25/20 Oppenheimer
Incyte price target lowered to $85 from $99 at Oppenheimer
MOR MorphoSys
$32.11 /

-0.715 (-2.18%)

INCY Incyte
$98.76 /

-1.63 (-1.62%)

MOR MorphoSys
$32.11 /

-0.715 (-2.18%)

MOR MorphoSys
$32.11 /

-0.715 (-2.18%)

INCY Incyte
$98.76 /

-1.63 (-1.62%)

INCY Incyte
$98.76 /

-1.63 (-1.62%)

Hot Stocks
Cboe Global Markets reaffirmed 2020 capital expenditures target » 14:06
08/02/20
08/02
14:06
08/02/20
14:06
CBOE

Cboe Global Markets

$86.67 /

-0.34 (-0.39%)

Cboe Global Markets…

Cboe Global Markets reaffirmed that capital expenditures are expected to be in the range of $65M-$70M, which includes expenditures associated with the company's Chicago headquarters relocation occurring later this year and its trading floor relocation planned for 2021. Adjusted operating expenses are now expected to be in the range of $436M-$444M, up $17M from the previous guidance of $419M-$427M, primarily reflecting the addition of EuroCCP and expenses related to the launch of pan-European derivatives trading and clearing. Cboe said in its July 31 earnings release, "The company updated or reaffirmed its guidance for the 2020 fiscal year as noted below. This guidance takes into account the company's acquisition of EuroCCP that closed on July 1, 2020 and its investment in launching pan-European derivatives trading and clearing, which is subject to regulatory approval."

ShowHide Related Items >><<
CBOE Cboe Global Markets
$86.67 /

-0.34 (-0.39%)

CBOE Cboe Global Markets
$86.67 /

-0.34 (-0.39%)

07/07/20 Piper Sandler
Cboe Global Markets downgraded to Neutral from Overweight at Piper Sandler
06/23/20
Fly Intel: Top five analyst downgrades
06/23/20 Goldman Sachs
Cboe Global Markets downgraded to Sell from Neutral at Goldman Sachs
06/10/20 BofA
HFCAA could primarily impact Nasdaq, IntercontinentalExchange, says BofA
CBOE Cboe Global Markets
$86.67 /

-0.34 (-0.39%)

CBOE Cboe Global Markets
$86.67 /

-0.34 (-0.39%)

CBOE Cboe Global Markets
$86.67 /

-0.34 (-0.39%)

CBOE Cboe Global Markets
$86.67 /

-0.34 (-0.39%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.